Literature DB >> 10656446

Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas.

H M Verheul1, K Hoekman, F Lupu, H J Broxterman, P van der Valk, A K Kakkar, H M Pinedo.   

Abstract

Angiogenesis and activated blood coagulation are involved in tumor growth and metastasis. Although some have suggested that activation of coagulation in tumors is not linked to activation of platelets, no data exist to either support or refute this concept. However, platelet turnover in cancer patients is often increased, and platelets are carriers of angiogenic growth factors. We hypothesized that platelets are involved in tumor-associated angiogenesis. To obtain evidence supporting this hypothesis, we have studied whether the angiogenic and coagulation pathways and platelets are concomitantly activated in cancer patients with soft tissue sarcomas (STSs) using a novel method to detect activated platelets in tumor specimens. Twelve patients with STS were selected on the basis of having intratumoral accumulation of fluid, which was aspirated. These accumulations demonstrated very high concentrations of vascular endothelial growth factor and coagulation factors (including thrombin-antithrombin-complex). Tumor specimens showed dense vascularization with intense vascular endothelial growth factor expression and the presence of activated platelets. Taken together, these results support the concept that angiogenesis, blood coagulation, and platelets are concomitantly activated in STS and support the hypothesis that platelets contribute to tumor-induced angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656446

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

Review 1.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

2.  Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.

Authors:  Qianghua Hu; Takeshi Hisamatsu; Monika Haemmerle; Min Soon Cho; Sunila Pradeep; Rajesha Rupaimoole; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Stephen T C Wong; Anil K Sood; Vahid Afshar-Kharghan
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

3.  Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer.

Authors:  Xiaoguang Yang; Helin Zhang; Fanyi Kong; Guochen Wang; Qianyu Gu; Zheng Zhao; Tiezhi Li; Mingming Ren; Zuosheng Li; Yang Guo
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer.

Authors:  Kazuhito Sasaki; Kazushige Kawai; Nelson H Tsuno; Eiji Sunami; Joji Kitayama
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

Review 5.  Contribution of platelets to tumour metastasis.

Authors:  Laurie J Gay; Brunhilde Felding-Habermann
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

6.  A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour.

Authors:  A H G Hansma; Y van Hensbergen; B C Kuenen; P J van Diest; R Hanemaaijer; S Meijer; H M Pinedo; K Hoekman
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

Review 7.  Colorectal cancer and hypercoagulability.

Authors:  Kazushige Kawai; Toshiaki Watanabe
Journal:  Surg Today       Date:  2013-05-14       Impact factor: 2.549

8.  The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.

Authors:  Akiko Kunita; Takeshi G Kashima; Yasuyuki Morishita; Masashi Fukayama; Yukinari Kato; Takashi Tsuruo; Naoya Fujita
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

Review 9.  Management of angiosarcoma.

Authors:  G Thomas Budd
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

10.  Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice.

Authors:  Deng-Bo Ji; Jia Ye; Yi-Min Jiang; Bo-Wen Qian
Journal:  BMC Complement Altern Med       Date:  2009-07-01       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.